Search results
Author(s):
Alexandre Persu
,
Fadl Elmula M Fadl Elmula
,
Yu Jin
,
et al
Added:
3 years ago
Renal sympathetic denervation (RDN) has been introduced as a novel approach to treat patients with so-called resistant hypertension.1–3 The first randomised clinical trial showed an impressive 32/12 mmHg fall in blood pressure after six months in the intervention group (n=52) compared to the control group (n=54). However, with the recent publication of the Symplicity HTN-3 study in the US4 the…
View more
Added:
5 months ago
Source:
AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.
Among the event’s highlights are eight late-breaking trial sessions, as listed below.
Watch our coverage of…
View more
Author(s):
Felix Mahfoud
Added:
1 year ago
In this short late-breaking interview, Prof Felix Mahfoud (Saarland University Hospital, DE) discusses the 3-year efficacy outcomes of the SPYRAL HTN-ON MED Pilot Study (NCT02439775). The global clinical study, presented at ACC.22, tested the long-term effect of renal denervation (Symplicity Spyral™ multi-electrode renal denervation system, Medtronic Vascular) on blood pressure reduction in…
View more
Author(s):
Markus P Schlaich
Added:
1 year ago
AHA 2022 — Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial (NCT03541174).This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan (Idorsia Pharmaceuticals Ltd.) in resistant hypertension.
Presented first at AHA 22, the trial showed that…
View more
Author(s):
Renata Cífková
Added:
3 years ago
Hypertension is the most prevalent cardiovascular disease affecting 20–50 % of the adult population.1 Elevated blood pressure has been identified as a risk factor for coronary heart disease (CHD), heart failure, stroke, peripheral arterial disease, renal failure and atrial fibrillation both in men and women in a large number of epidemiological studies.2–4 So far, the largest meta-analysis of…
View more
Author(s):
Peter M Nilsson
Added:
3 years ago
Patients with type 2 diabetes have a well-documented increased risk for cardiovascular disease (CVD) that is more than two to three times higher than the risk seen in non-diabetic subjects.1 In spite of modern methods to treat diabetes and its complications, the increased risk is still substantial even if data on risk factor controls in national surveys have shown improving trends for blood…
View more
Author(s):
Naomi Abe
,
John D Bisognano
Added:
3 years ago
Hypertension is the most common chronic disease in the US, affecting 29% of the adult population.1 Once considered a benign, compensatory mechanism for ageing, high blood pressure (BP) is now recognised as an important risk factor for cardiovascular disease. It is estimated that inadequate BP control is responsible for 62% of cases of cerebrovascular disease, 49% of cases of ischemic heart…
View more
Author(s):
Thomas Münzel
,
Mette Sørensen
Added:
3 years ago
The health burden of environmental noise has recently been quantified in a report of the World Health Organization (WHO) in terms of disabilityadjusted life years (DALYs; i.e., the number of years lost because of disability or death – a measure that combines both morbidity and mortality). The WHO estimates that – in western Europeans – each year 45,000 DALYs are lost because of noise-induced…
View more
Author(s):
Alejandro de la Sierra
Added:
3 years ago
Despite the presence of an artificial debate developed in the past decade1,2 focusing on calcium channel blockers and their role in the prevention and treatment of cardiovascular diseases, a huge amount of evidence has been created favouring this class of agents in the treatment of hypertension and associated cardiovascular diseases.3 Calcium channel blockers are divided into three classes, the…
View more
Author(s):
Purvi Parwani
Added:
4 months ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac…
View more